Pfizer Inc
NYSE: PFE
$29.42
-$0.24 (-0.8%)
Closing Price on September 20, 2024
PFE Articles
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Published:
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Published:
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Intel, Pfizer and Microsoft above all other Dow stocks.
Published:
Last Updated:
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Published:
Last Updated:
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers still favored Pfizer, Intel and Microsoft above all other Dow stocks.
Published:
Last Updated:
Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas, 10 tied mostly to retailing of apparel and accessories, and six are tied to pharmaceuticals and biotech.
Published:
Last Updated:
GlycoMimetics shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease trial in conjunction with Pfizer.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday included Cisco Systems, Duke Energy, Goodyear, Illumina, Kinder Morgan, Micron Technology, Pfizer and Tencent Music.
Published:
Last Updated:
Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make...
Published:
Last Updated: